Evaluating the role of prereduction hip traction in the management of infants and children with developmental dysplasia of the hip (DDH): protocol for a systematic review and planned meta-analysis. Issue 1 (29th January 2018)

• Record Type: Journal Article
• Authors: Walton, Sarah; Schaeffer, Emily; Mulpuri, Kishore; Cundy, Peter; Williams, Nicole
• Is Part Of: BMJ open. Volume 8:Issue 1(2018)
• Publication Date: 2018-01-29
• Subjects: paediatric orthopaedics -- developmental dysplasia of the hip (ddh) -- preoperative traction -- avascular necrosis (avn) -- closed reduction -- systematic review; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2017-019599
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Developmental dysplasia of the hip (DDH) affects 4–6 per 1000 live births in developed countries. Effective treatment to realign the hip is necessary to avoid long-term morbidities and maximise functional outcome. Treatment options depend on patient age but typically involve hip bracing and/or reduction under general anaesthetic. Some centres also employ prereduction hip traction. Historical papers suggest traction reduces risk of avascular necrosis (AVN) femoral head and reduces requirement for open reduction. However, several studies including a large retrospective cohort study, dispute this. We propose to perform the first systematic review and meta-analysis to clarify the value of prereduction hip traction in the management of DDH in children under the age of 3 years by identifying whether it impacts on the rate of successful closed reduction (CR) and risk of AVN. Methods and analysis: We will search MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials to identify potentially relevant studies. Studies reporting on incidence of successful CR, AVN femoral head and complications associated with prereduction hip traction in children of less than 3 years with DDH will be eligible for inclusion. Only randomised controlled trials, prospective and retrospective case–control and comparative cohort studies will be included in quantitative review. There will be no study design restrictions for inclusion in qualitative review. Following study selection, full-text paper retrieval, data extraction and synthesis, studies will be assessed for risk of bias and heterogeneity. If the included studies are sufficiently homogeneous, then we will perform meta-analysis. A narrative synthesis of the systematic review's results will also be presented. Ethics and dissemination: Formal ethical approval is not required as primary patient data will not be collected. The systematic review's results will be disseminated through a peer-reviewed publication. Trial registration number: CRD42017064254 ; Pre-results.